A Study to Evaluate the Efficacy of PanCytoVir™ for the Treatment of Non-Hospitalized Patients With COVID-19 Infection

NCT05442983 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: PanCytoVir™ (probenecid)
DRUG: Placebo

Sponsor

TrippBio, Inc.